Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HTJXN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
TQB2103
|
|||||
| Synonyms |
TQB 2103; TQB-2103; TQB2103
Click to Show/Hide
|
|||||
| Organization |
Nanjing Shunxin Pharmaceutical Co., Ltd.; Sino Biopharmaceutical Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
A humanized anti-CLDN18.2 IgG1 monoclonal antibody
|
Antibody Info | ||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
2-DDDX-d
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
